20 Results for "

ERβ antagonists

" in MedChemExpress (MCE) Product Catalog:
Products (20)

20 Results for "ERβ antagonists" in MCE Product Catalog:

34
34 Publications Verification
Cat. No.: HY-103456
CAS No.: 805239-56-9
Purity:  99.70%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

PHTPP is a selective estrogen receptor β (ERβ) antagonist with 36-fold selectivity over ERα .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-B0412
CAS No.: 50-27-1
Synonyms: Oestriol
Estriol (Oestriol), an orally active estrogen, is a ERα and ERβ agonist. Estriol is a potent GPR30 antagonist in estrogen receptor-negative breast cancer cells. Estriol can ameliorate disease severity through immunomodulatory mechanisms that decrease tissue inflammation. Estriol has powerful proconvulsant effects .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-114263
CAS No.: 1454925-59-7
Purity:  99.07%
Target:  

PPAR

Research Areas:  

Cancer

NXT629 is a potent, selective, and competitive PPAR-α antagonist, with an IC50 of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC50s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively . NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16023A
CAS No.: 182167-02-8
Synonyms: EM-652; SCH 57068
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Acolbifene (EM-652), the active metabolite of EM800, is an orally active pure antiestrogen and selective estrogen receptor antagonist. Acolbifene (EM-652) inhibits estradiol (E2)-induced transcriptional activity of ERα (IC50 = 2 nM) and ERβ (IC50 = 0.4 nM). Acolbifene (EM-652) possesses potent and pure anticarcinogenic properties .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0910
CAS No.: 155683-00-4
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 + T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca 2+ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y12 receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .
loading...
    loading...
Cat. No.: HY-15731
CAS No.: 15183-37-6
Purity:  99.76%
Estetrol, an orally active estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol binds ERα as well as ERβ (with a fourfold lower affinity). Estetrol increases eNOS expression/activity and NO synthesis in endothelial cells. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast. Estetrol can be used in contraception and menopausal hormone research .
loading...
    loading...
Cat. No.: HY-103457
CAS No.: 849662-80-2
Purity:  98.34%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Y134 is a selective and orally active oestrogen receptor (ER) modulator (SERM), exhibits potent antagonist activity at ERα and ERβ. Y134 shows 121.1-fold selectivity for ERα (Ki=0.09 nM) over ERβ (Ki=11.31 nM). Y134 inhibits oestrogen-stimulated proliferation of ER-positive human breast cancer cells .
loading...
    loading...
Cat. No.: HY-P4190
CAS No.: 163973-98-6
Target:  

GnRH Receptor

Research Areas:  

Endocrinology

FSH receptor-binding inhibitor fragment(bi-10) is a potent FSH antagonist. FSH receptor-binding inhibitor fragment(bi-10) blocks the binding of FSH to FSHR, and alteres FSH action at the receptor level. FSH receptor-binding inhibitor fragment(bi-10) results in the suppression of ovulation and causes follicular atresia of mice. FSH receptor-binding inhibitor fragment(bi-10) has the potential for utilizing to restrain the carcinogenesis of ovarian cancer by down-regulating overexpression of FSHR and ERβ in the ovaries .
loading...
    loading...
Cat. No.: HY-150693
CAS No.: 2580941-14-4
Purity:  98.39%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Estrogen receptor β antagonist 2 is a potent and selective estrogen receptor β (ERβ) antagonist with IC50s of 109.10, 0.63 µM for Erα and Erβ, respectively .
loading...
    loading...
Cat. No.: HY-W114419
CAS No.: 79-97-0
Bisphenol C is an estrogen receptor-α (ERα) agonist and an ERβ antagonist, with IC50 values of 2.65 nM for ERα and 1.94 nM for ERβ. Bisphenol C is a material of manufacturing polyester polymers like polycarbonate, is widely used in daily items like water bottles, food packaging, textile and so on .
loading...
    loading...
Cat. No.: HY-125627
CAS No.: 305822-63-3
CP-394531 is an efficient and highly selective non-steroidal glucocorticoid receptor (GR) antagonist, with a Ki value of 0.1 nM. CP-394531 has a weak binding to androgen receptor (AR) (Ki = 130 nM), and has almost no effect on progesterone receptor (PR) and estrogen receptors (ERα, ERβ). CP-394531 completely blocks the half-maximal agonistic effect induced by Dexamethasone (HY-14648G), with a Kif of 4.1 nM. CP-394531 can be used to study various diseases such as diabetes, obesity, depression, neurodegenerative diseases, glaucoma and Cushing's disease .
loading...
    loading...
Cat. No.: HY-119528
CAS No.: 5090-88-0
Mansonone F acts as an estrogen receptor antagonist and an antimicrobial agent. Mansonone F effectively inhibits 17β-estradiol-induced β-galactosidase activity. Derivatives of Mansonone F also exhibit antioxidant and anti-Staphylococcus aureus biological activities. Mansonone F can be used in studies related to Staphylococcus aureus infections and methicillin-resistant Staphylococcus aureus (MRSA) infections .
loading...
    loading...
Cat. No.: HY-169941
CAS No.: 2482778-93-6
Target:  

Estrogen Receptor/ERR

Research Areas:  

Metabolic Disease Cancer

ERα/ERβ antagonist-1 (Compound 10) is partial antagonists of ERα and ERβ. ERα/ERβ antagonist-1 reduces ERα and ERβ activity in a dose-dependent manner in HepG2 liver cells .
loading...
    loading...
Cat. No.: HY-173474
CAS No.: 2412715-30-9
Research Areas:  

Cancer

ERβ agonist-1 (Compound 8) is a dual-active selective ERβ agonist (EC50: 46.8 nM) and AR antagonist (IC50: 1555 nM). ERβ agonist-1 activates ERβ signaling by binding to ERβ and inhibits AR activity. ERβ agonist-1 retains selective ERβ agonist activity in mouse models and can be used to study prostate cancer .
loading...
    loading...
Cat. No.: HY-103451
CAS No.: 221368-54-3
Purity:  ≥99.0%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Metabolic Disease

(R,R)-THC is an ERα agonist and an ERβ antagonist, with Kis of 9.0 nM and 3.6 nM for ERα and ERβ, respectively. (R,R)-THC has higher relative binding affinity for ERβ than ERα with the values of 25 and 3.6 .
loading...
    loading...
Cat. No.: HY-103451A
CAS No.: 138090-06-9
Target:  

Estrogen Receptor/ERR

Research Areas:  

Metabolic Disease

rel-(R,R)-THC is the relative configuration of (R,R)-THC (HY-103451). (R,R)-THC is an ERα agonist and an ERβ antagonist, with Kis of 9.0 nM and 3.6 nM for ERα and ERβ, respectively. (R,R)-THC has higher relative binding affinity for ERβ than ERα with the values of 25 and 3.6 .
loading...
    loading...
Cat. No.: HY-103456R
CAS No.: 805239-56-9
Research Areas:  

Cancer

PHTPP (Standard) is the analytical standard of PHTPP. This product is intended for research and analytical applications. PHTPP is a selective estrogen receptor β (ERβ) antagonist with 36-fold selectivity over ERα .
loading...
    loading...
Cat. No.: HY-114631
CAS No.: 182167-03-9
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

EM-800, an orally active anti-estrogen, serves as an antagonist to the transcriptional functions of estrogen receptors α (ERα) and β (ERβ). EM-800 possesses anticancer activity, capable of inhibiting the growth of breast cancer induced by 7,12-Dimethylbenz[a]anthracene (DMBA) (HY-W011845). Furthermore, in ovariectomized animals, EM-800 effectively slows down bone loss. Additionally, EM-800 shows potential in the research of breast and endometrial cancers, while exerting beneficial effects on bone and lipid metabolism .
loading...
    loading...
Cat. No.: HY-15731S1
CAS No.: 2734920-42-2
Estetrol-d4 (Major) is the deuterium labeled Estetrol (HY-15731). Estetrol, an orally active estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol binds ERα as well as ERβ (with a fourfold lower affinity). Estetrol increases eNOS expression/activity and NO synthesis in endothelial cells. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast. Estetrol can be used in contraception and menopausal hormone research .
loading...
    loading...
Cat. No.: HY-164726
CAS No.: 96719-63-0
Target:  

Estrogen Receptor/ERR

Research Areas:  

Others

Estrogen receptor modulator 11 (Compound 27) is a tetrahydroisoquinoline derivative. Estrogen receptor modulator 11 has a certain affinity for estrogen receptors (ER), with IC50 values of 285 nM and 421 nM for ERα and ERβ, respectively. Estrogen receptor modulator 11 lacks antagonist activity in the MCF-7 cellular assay .
loading...
    loading...
  • 1